Video Library

'Exciting' Clinical Trials

 MD Anderson’s Tapan Kadia, MD, highlights a few clinical trials that have the potential to change the standards of care.

Predictions for Next Achievement in Leukemia

 Tapan Kadia, MD, associate professor, Department of Leukemia, MD Anderson Cancer Center, is hopeful that the next big milestone “will be the cure of one of these diseases.”

Addressing Relapsed Disease

Tapan Kadia, MD, associate professor, Department of Leukemia, MD Anderson Cancer Center, discusses the challenges of preventing and treating relapsed disease.

A Better Knowledge of Leukemia

The pace of progress has been “breathtaking,” says Tapan Kadia, MD, associate professor, Department of Leukemia, MD Anderson Cancer Center.

Revolutions in AML, ALL

Hear the latest advancements in leukemia treatments from Tapan Kadia, MD, associate professor, Department of Leukemia, MD Anderson Cancer Center. 

CLL Milestones

Paolo Strati, MD, from The University of Texas MD Anderson Cancer Center, shares what he predicts will be the next big achievements or milestones in CLL.

Clinical Trials of Interest

At MD Anderson, the intent is ‘to have a clinical trial available for everybody who comes through the door,’ says its section chief, Chronic Lymphocytic Leukemia, Department of Leukemia, Division of Cancer Medicine, William G. Wierda, MD, PhD.

Accelerated Pace of Advances

William G. Wierda, MD, PhD, section chief, Chronic Lymphocytic Leukemia, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, discusses the exciting advances in CLL over the past 5 years.

CLL Clinical Trials

Paolo Strati, MD, a recipient of ASCO’s Young Investigator Award, describes two CLL clinical trials under way.

Complete Remission Complications, Concerns

Despite significant progress in CLL, there are still several unmet needs, says The University of Texas MD Anderson Cancer Center’s Paolo Strati, MD.

A Major Revolution

The University of Texas MD Anderson Cancer Center’s Paolo Strati, MD, describes how the treatment of patients with CLL has ‘meaningfully changed’ over the last few years.

CLL Treatment Advancements

William G. Wierda, MD, PhD, section chief - Chronic Lymphocytic Leukemia, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, explores the latest advancements in chronic lymphocytic leukemia treatment.

A 'Better Toolbox' for Physicians

Newly approved drugs to improve patient treatment options are described.

Clinical Research in CLL 'Moving Fast'

The pace of progress in CLL research is rapidly growing. Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, explores contributing factors.

Reverse Inhibitors?

William G. Wierda, MD, PhD, section chief, Chronic Lymphocytic Leukemia, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, explores some exciting strategies being considered in treating CLL.

The High Risk Patient

 MD Anderson Cancer Center’s William G. Wierda, MD, PhD, addresses the high-risk groups in CLL. 

Treatment Advancements

Sidney Kimmel Cancer Center at Jefferson Health’s Pierluigi Porcu, MD, shares insight into the latest advancements in leukemia and lymphoma treatment.

Identifying, Addressing Challenges

Pierluigi Porcu, MD, Sidney Kimmel Cancer Center at Jefferson Health, identifies ‘unmet needs’ and what’s being done to address those areas.

Loading